comprehensive -WSS

comprehensive

author：explore 2025-09-30 17:27:24 - browse：3215

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The Bio Revolution is changing business and society

focus

WSS

Bird flu makes raw milk dangerous to consume, mouse study finds

The Bio Revolution is changing business and society

Devoted Health’s losses in Medicare Advantage persist

Medical students need to learn the potent medicine of empathy

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Readout Newsletter: Amgen, Regeneron, BGI Group and more

knowledge

comprehensive

entertainment

Peter Hotez and the public health issue of online harassment

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

After affirmative action ruling, medical educators look to 'holistic review'

The Bio Revolution is changing business and society

BioMarin wins approval for gene therapy to treat hemophilia A

Guardant Health colon cancer test endorsed by FDA advisory panel

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why Novartis is going to walk from its acquisition of MorphoSys

Drug repurposing or repositioning? The language matters

Stroke rates rising, especially in working

focus

Congress: Prevent baby formula shortages by passing a new bill

Congress: Prevent baby formula shortages by passing a new bill

The world needs the new pandemic treaty

Hospitals need to get ahead of regulations on climate change

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Top private equity targets in 2023: cardiology, clinical trials, lasers

focus

focus

hotspot

explore